MichaelDiGiovannaMDPhD

Breast Cancer

Professor, Comprehensive Cancer Center, Yale University School of Medicine

Telehealth Available

Overview of Dr. DiGiovanna

Dr. Michael DiGiovanna is an oncologist in New Haven, CT and is affiliated with multiple hospitals in the area, including Yale-New Haven Hospital and Smilow Cancer Hospital. He received his medical degree from Yale School of Medicine and has been in practice 27 years. Dr. DiGiovanna accepts several types of health insurance, listed below. He is one of 145 doctors at Yale-New Haven Hospital and one of 7 doctors at Smilow Cancer Hospital who specialize in Oncology. He has more than 60 publications and over 500 citings.

Office
800 Howard Ave
Yale Physicians Building 2ND floor
New Haven, CT 06519
Book by Phone+1(405) 896-3827

Fax+1 203-737-2617

Education & Training

Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 1995 - 1997
Yale-New Haven Medical CenterResidency, Internal Medicine, 1991 - 1993
Yale School of MedicineClass of 1990

Certifications & Licensure

CT State Medical License 1993 - 2025
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread Start of enrollment: 2018 Nov 28
Completed
Phase 2

Publications & Presentations

PubMed

66 citations
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Bra...
Nancy U Lin, Rashmi K Murthy, Vandana Abramson, Carey Anders, Thomas Bachelot
JAMA Oncology. 2023-02-01
307 citations
Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER...
Nan Lin, Virginia F. Borges, Carey K. Anders, Rashmi Krishna Murthy, Elisavet Paplomata
Journal of Clinical Oncology. 2020-05-29
1368 citations
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
Gunter von Minckwitz, Chiun Sheng Huang, Max S. Mano, Sibylle Loibl, Eleftherios P. Mamounas
The New England Journal of Medicine. 2019-02-14

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Connecticare FlexPOS
Empire BCBS HMO
Empire BCBS PPO
First Health PPO
GHI PPO
Great West PPO
HIP of New York - Select PPO
Humana ChoiceCare Network PPO
MagnaCare PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment